Jazz Pharmaceuticals Agrees to $145 Million Settlement in Antitrust Case

The lawsuit concerning the distribution of the narcolepsy treatment drug Xyrem against Jazz Pharmaceuticals (‘Jazz’) by a group of indirect purchasers reached a settlement of $145 million. The suit pertained to allegations against Jazz for engaging in an anti-competitive “pay-for-delay” scheme, where Jazz made arrangements to delay the market entry of lower-cost generic versions of Xyrem.